{"organizations": [], "uuid": "90107329c41aaf2551db7f66aa4cd046a5937e11", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-precipio-in-strategic-partnership/brief-precipio-in-strategic-partnership-discussions-for-proprietary-cytogenetics-media-iv-cell-idUSFWN1RV0JO", "country": "US", "domain_rank": 408, "title": "BRIEF-Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T14:44:00.000+03:00", "replies_count": 0, "uuid": "90107329c41aaf2551db7f66aa4cd046a5937e11"}, "author": "", "url": "https://www.reuters.com/article/brief-precipio-in-strategic-partnership/brief-precipio-in-strategic-partnership-discussions-for-proprietary-cytogenetics-media-iv-cell-idUSFWN1RV0JO", "ord_in_thread": 0, "title": "BRIEF-Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "eikon", "sentiment": "none"}, {"name": "ytogenetics media iv-cell reuters staff    precipio inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 45 AM / Updated 9 minutes ago BRIEF-Precipio In Strategic Partnership Discussions For Proprietary Cytogenetics Media IV-Cell Reuters Staff \n  Precipio Inc: \n* PRECIPIO IN STRATEGIC PARTNERSHIP DISCUSSIONS FOR PROPRIETARY CYTOGENETICS MEDIA IV-CELL \n* PRECIPIO - IN ACTIVE LICENSING DISCUSSIONS WITH SEVERAL POTENTIAL PARTNERS REGARDING IV-CELL, COâ€™S PROPRIETARY CYTOGENETICS MEDIA \n* PRECIPIO - EXTERNAL VALIDATIONS & EVALUATIONS ARE WITH COMMERCIAL DISCUSSIONS TO OUT-LICENSE RIGHTS, EXPECTED TO BE COMPLETED WITHIN CURRENT QUARTER Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-18T14:44:00.000+03:00", "crawled": "2018-04-18T15:00:01.011+03:00", "highlightTitle": ""}